-
Big Pharma can gain from tango with small fry
- 1 year ago
Indias largest pharmaceutical industry body, the Indian Drug Manufacturers Association, presents a picture of vivid contrasts.
-
Clinical trials in India a delicate line to tread
- 1 year ago
What started as a rare reporting subject only a few years ago has become a frequent fixture for newspapers and magazines ethics in clinical trials in India.
-
Comment: As pharma buyouts taper, focus shifts to smaller firms
- 1 year ago
While cross-border deals did not completely subside in the last one year, a long pause is becoming apparent.
-
Affordable medicines will take more than price controls
- 1 year ago
The draft National Pharmaceutical Pricing Policy floated in October by the Department of Pharmaceuticals inviting feedback from stakeholders charts out significant changes
-
Make no mistake, multinational drugmakers are very alive to markets such as India
- 2 years ago
Department of Industrial Policy and Promotions apprehension that these companies will ignore local needs and focus only on exports is unfounded.
-
Genzyme is just the booster that Sanofi Aventis needs now
- 2 years ago
Orphan-drug maker, with a strong pipeline and sales of $4.5 billion, will be a prize catch
-
Government alone cant fight cancer, diabetes and strokes
- 2 years ago
There should be all-round effort and companies should think beyond the bottomline.
-
Despite FDA vote, the words caution on Avandia
- 2 years ago
Its important to put the safety of the patients before any opinion is shared arbitrarily.
-
Move to better access to drugs a welcome change
- 2 years ago
Study shows greater willingness among companies to open up
-
Stage set for bigger biotechnology play by local companies
- 2 years ago
If they surmount the development and launch hiccups, it could well be generics redux.